Insider Buy/Sell Details for the Biotechnology Industry — Last 30 Days
Ratio0.1:1
Daily Buy & Sell Volume
Transactions (1051)
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
100
Price
$156.00
Total Value
$15.60K
Shares Held After
666
% of Holdings
13.1%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
100
Price
$155.97
Total Value
$15.60K
Shares Held After
766
% of Holdings
11.5%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
240
Price
$154.41
Total Value
$37.06K
Shares Held After
866
% of Holdings
21.7%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
128
Price
$153.42
Total Value
$19.64K
Shares Held After
1,106
% of Holdings
10.4%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
424
Price
$152.67
Total Value
$64.73K
Shares Held After
1,234
% of Holdings
25.6%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
8
Price
$151.57
Total Value
$1.21K
Shares Held After
1,658
% of Holdings
0.5%
Avalo Therapeutics, Inc. (AVTX)
Chan Mitchell — Director
Shares
3,167
Price
$22.88
Total Value
$72.46K
Shares Held After
3,166
% of Holdings
50.0%
Avalo Therapeutics, Inc. (AVTX)
Sullivan Christopher Ryan — Chief Financial Officer
Shares
8,900
Price
$22.57
Total Value
$200.91K
Shares Held After
423
% of Holdings
95.5%
Avalo Therapeutics, Inc. (AVTX)
Sullivan Christopher Ryan — Chief Financial Officer
Shares
9,219
Price
$21.37
Total Value
$197.01K
Shares Held After
9,323
% of Holdings
49.7%
Avalo Therapeutics, Inc. (AVTX)
Sullivan Christopher Ryan — Chief Financial Officer
Shares
2,700
Price
$20.76
Total Value
$56.05K
Shares Held After
18,542
% of Holdings
12.7%
Avalo Therapeutics, Inc. (AVTX)
Sullivan Christopher Ryan — Chief Financial Officer
Shares
12,347
Price
$19.28
Total Value
$238.09K
Shares Held After
21,242
% of Holdings
36.8%
Avalo Therapeutics, Inc. (AVTX)
Sullivan Christopher Ryan — Chief Financial Officer
Shares
13,834
Price
$18.55
Total Value
$256.66K
Shares Held After
33,589
% of Holdings
29.2%
Avalo Therapeutics, Inc. (AVTX)
VARKI PAUL — Chief Legal Officer
Shares
400
Price
$23.71
Total Value
$9.48K
Shares Held After
3,634
% of Holdings
9.9%
Avalo Therapeutics, Inc. (AVTX)
VARKI PAUL — Chief Legal Officer
Shares
9,253
Price
$22.70
Total Value
$210.03K
Shares Held After
4,034
% of Holdings
69.6%
Avalo Therapeutics, Inc. (AVTX)
VARKI PAUL — Chief Legal Officer
Shares
22,839
Price
$21.22
Total Value
$484.54K
Shares Held After
13,287
% of Holdings
63.2%
Avalo Therapeutics, Inc. (AVTX)
VARKI PAUL — Chief Legal Officer
Shares
5,196
Price
$19.78
Total Value
$102.78K
Shares Held After
36,126
% of Holdings
12.6%
Avalo Therapeutics, Inc. (AVTX)
VARKI PAUL — Chief Legal Officer
Shares
37,375
Price
$18.91
Total Value
$706.84K
Shares Held After
41,322
% of Holdings
47.5%
Avalo Therapeutics, Inc. (AVTX)
Doyle Mittie — Chief Medical Officer
Shares
10,058
Price
$22.88
Total Value
$230.13K
Shares Held After
3,622
% of Holdings
73.5%
Avalo Therapeutics, Inc. (AVTX)
Doyle Mittie — Chief Medical Officer
Shares
19,015
Price
$22.41
Total Value
$426.05K
Shares Held After
13,680
% of Holdings
58.2%
Avalo Therapeutics, Inc. (AVTX)
Doyle Mittie — Chief Medical Officer
Shares
44,944
Price
$21.20
Total Value
$952.67K
Shares Held After
32,695
% of Holdings
57.9%
Avalo Therapeutics, Inc. (AVTX)
Doyle Mittie — Chief Medical Officer
Shares
5,000
Price
$19.65
Total Value
$98.25K
Shares Held After
77,639
% of Holdings
6.1%
Avalo Therapeutics, Inc. (AVTX)
Doyle Mittie — Chief Medical Officer
Shares
27,538
Price
$18.03
Total Value
$496.41K
Shares Held After
82,639
% of Holdings
25.0%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
40
Price
$603.82
Total Value
$24.15K
Shares Held After
40,513
% of Holdings
0.1%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
80
Price
$599.26
Total Value
$47.94K
Shares Held After
40,553
% of Holdings
0.2%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
460
Price
$598.21
Total Value
$275.17K
Shares Held After
40,633
% of Holdings
1.1%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
680
Price
$597.47
Total Value
$406.28K
Shares Held After
41,093
% of Holdings
1.6%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
560
Price
$596.05
Total Value
$333.79K
Shares Held After
41,773
% of Holdings
1.3%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
1,513
Price
$595.02
Total Value
$900.27K
Shares Held After
42,333
% of Holdings
3.5%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
346
Price
$594.09
Total Value
$205.55K
Shares Held After
43,846
% of Holdings
0.8%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
80
Price
$592.26
Total Value
$47.38K
Shares Held After
44,192
% of Holdings
0.2%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
101
Price
$591.60
Total Value
$59.75K
Shares Held After
44,272
% of Holdings
0.2%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
320
Price
$590.36
Total Value
$188.92K
Shares Held After
44,373
% of Holdings
0.7%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
410
Price
$589.18
Total Value
$241.56K
Shares Held After
44,693
% of Holdings
0.9%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
470
Price
$588.19
Total Value
$276.45K
Shares Held After
45,103
% of Holdings
1.0%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
805
Price
$586.78
Total Value
$472.36K
Shares Held After
45,573
% of Holdings
1.7%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
927
Price
$585.53
Total Value
$542.79K
Shares Held After
46,378
% of Holdings
2.0%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
873
Price
$584.64
Total Value
$510.39K
Shares Held After
47,305
% of Holdings
1.8%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
796
Price
$583.73
Total Value
$464.65K
Shares Held After
48,178
% of Holdings
1.6%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
159
Price
$582.73
Total Value
$92.65K
Shares Held After
48,974
% of Holdings
0.3%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
296
Price
$581.28
Total Value
$172.06K
Shares Held After
49,133
% of Holdings
0.6%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
384
Price
$580.07
Total Value
$222.75K
Shares Held After
49,429
% of Holdings
0.8%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
120
Price
$579.12
Total Value
$69.49K
Shares Held After
49,813
% of Holdings
0.2%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
80
Price
$576.32
Total Value
$46.11K
Shares Held After
49,933
% of Holdings
0.2%
MapLight Therapeutics, Inc. (MPLT)
Setia Vishwas — Chief Financial Officer
Shares
2,068
Price
$29.07
Total Value
$60.12K
Shares Held After
356,256
% of Holdings
0.6%
MapLight Therapeutics, Inc. (MPLT)
Setia Vishwas — Chief Financial Officer
Shares
8,496
Price
$28.04
Total Value
$238.23K
Shares Held After
358,324
% of Holdings
2.3%
MapLight Therapeutics, Inc. (MPLT)
Lillie James Woodruff — Chief Scientific Officer
Shares
16,421
Price
$29.13
Total Value
$478.34K
Shares Held After
243,450
% of Holdings
6.3%
MapLight Therapeutics, Inc. (MPLT)
Foff Erin Pennock — Chief Medical Officer
Shares
15,900
Price
$29.13
Total Value
$463.17K
Shares Held After
350,497
% of Holdings
4.3%
MapLight Therapeutics, Inc. (MPLT)
Lillie James Woodruff — Chief Scientific Officer
Shares
8,390
Price
$28.04
Total Value
$235.26K
Shares Held After
259,871
% of Holdings
3.1%
MapLight Therapeutics, Inc. (MPLT)
Foff Erin Pennock — Chief Medical Officer
Shares
8,152
Price
$28.04
Total Value
$228.58K
Shares Held After
366,397
% of Holdings
2.2%
MapLight Therapeutics, Inc. (MPLT)
Kroeger Christopher A. — Director
Shares
15,603
Price
$29.13
Total Value
$454.52K
Shares Held After
1,580,820
% of Holdings
1.0%
Showing 351–400 of 1051 transactions (page 8 of 22)